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We would like to thank Mr Chong and colleagues for
their comments. The main point of their comments,
seem to relate to the fact that we did not include
their instrument, the ICQ, in our paper assessing
disease specific instruments for claudication. We
chose the instruments for study early in 2002 before
the ICQ was published. We were, however, aware of
the ICQ from published abstracts and did approach
the authors for permission and assistance in includ-
ing the ICQ in our studies. We did not receive a
timely response.
A small number of claudicants will deteriorate and
progress to critical ischaemia thus we are of the
opinion that any disease specific QOL instrument
should be able to detect this change. The sensitivity to
negative change of any instrument not assessing
critical ischaemia needs to be closely examined. We
are not aware of any publications comparing the ICQ
to other disease specific QOL instruments (we
consider the WIQ to be a paper treadmill test rather
than a QOL measure) thus to claim the ‘ICQ is
currently the best condition specific instrument’
requires further justification.
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We read with interest the paper from Mehta et al.
recommending the VASCUQUOL as the most
responsive disease specific instrument for evaluating
quality of life (QOL) changes in intermittent
claudication (IC).
Although we agree with the authors that one of the
main aims of treating IC is to reverse its detrimental
effect on QOL, we are rather surprised that in their
search of a suitable disease-specific instrument for this
condition, there was no evaluation of the intermittent
claudication questionnaire (ICQ) in their study. The
ICQ is a patient assessed, 16-item instrument that takes
an average time of 3.7 min to completewith a test-retest
intraclass correlation of 0.95 and Cronbach’s alpha of
0.94.1 In recently published randomised studies
evaluating the impact of treating IC, Cheetham et al.2
and Kakkos et al.3 have shown that the ICQ was
superior to the SF-36 in being able to detect subtle but
important QOL changes in claudicants following
intervention. If a suitable disease-specific instrument
is available, it may be time to abandon the use of
lengthy, non-responsive generic instruments in labour
intensive IC trials.
Although across the Atlantic, the WIQ (Walking
Impairment Questionnaire) is the preferred disease-
specific instrument for evaluation of QOL in IC, we
agreewith the authors’ conclusion in a previous review
that the WIQ is really only a measure of walking
performance and not strictly a QOL measure.4
Although walking impairment is a feature of IC,
evaluation of this function alone does not fully address
claudicants’ concerns regarding QOL impairment. For
example, a maximumwalking distance of 50 mmay be
a handicap to one patient, but may be perfectlyEur J Vasc Endovasc Surg 32, 110–111 (2006)
doi:10.1016/j.ejvs.2006.02.005, available online at http://www.sciencedirect.com oned.
Correspondence 111acceptable to another patient. Treatment should aim to
improve overall QOL in patients and walking speed,
walkingdistance or stair climbing ability as assessed by
the WIQ form only aspects of that improvement.
Our reservations about the recommendation of the
VASCUQUOL as the disease-specific instrument of
choice in IC stem from the fact that it ismethodologically
flawed at its inception as Mehta et al. correctly observe
that it is ‘designed for use across the whole spectrum of
patients with peripheral vascular disease, i.e. claudi-
cants and patients with critical ischaemia’. The VASCU-
QUOL’s suitability and validity as a specific outcome
measure for IC trials is debatable as claudicants are not
primarily concerned by the problems of tissue loss, rest
pain and limb loss present in the critically ischaemic.
Fourout of 25questions in theVascuQol probeproblems
of rest pain and tissue loss that are not relevant to IC.
Therefore, its ability to detect small but important
changes in QOL impairment in claudicants over time
and following treatment is questionable.
The ICQ was developed in response to the lack of a
suitable disease specific QOL instrument in IC. The
ideal instrument for measuring health related QOL
outcome in IC should be self-administered, easily
comprehensible with a brief completion and scoring
time, reliable (able to measure the impact of IC on QOL
in a reproduciblemanner), valid (measures the effect of
IC on QOL) and responsive (able to detect small but
important changes in health due to IC over time or
treatment). The ICQ is currently the best condition-
specific instrument rigorously tested for all these
properties that assesses the effect of IC on QOL from a
patient’s perspective. We recommend that future trials*Corresponding author. Dr P.F.S. Chong, Department of Vascular
Surgery, Imperial College School of Medicine, Charing Cross
Hospital, Fulham Palace Road, London, UK.of IC should includemeasurement of QOL and that the
ICQ should be considered when considering outcome
assessment for health related QOL.
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